

# Alexandra Sevko

## List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11046823/alexandra-sevko-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18

papers

1,659

citations

16

h-index

18

g-index

18

ext. papers

1,917

ext. citations

6.2

avg, IF

4.49

L-index

#	Paper	IF	Citations
18	The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. <i>Molecular Cell</i> , 2017, 65, 730-742.e5	17.6	122
17	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). <i>OncolImmunology</i> , 2017, 6, e1326440	7.2	51
16	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. <i>OncolImmunology</i> , 2015, 4, e1008371	7.2	182
15	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , 2015, 21, 5453-9	12.9	237
14	Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 1021-7	1.2	33
13	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 1021-1027	1.2	13
12	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. <i>Oncotarget</i> , 2014, 5, 4516-28	3.3	20
11	Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1610-9	4.3	79
10	Tumor microenvironment and myeloid-derived suppressor cells. <i>Cancer Microenvironment</i> , 2013, 6, 169-77	1	90
9	Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 457-63	4.5	9
8	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. <i>Journal of Immunology</i> , 2013, 190, 2464-71	5.3	156
7	Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. <i>Journal of Cancer</i> , 2013, 4, 3-11	4.5	80
6	Melanoma-induced immunosuppression and its neutralization. <i>Seminars in Cancer Biology</i> , 2012, 22, 319-26	1	89
5	Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 275-282	7.4	50
4	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. <i>Journal of Immunotoxicology</i> , 2012, 9, 292-300	3.1	98
3	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. <i>Journal of Immunotoxicology</i> , 2012, 9, 275-81	3.1	45
2	Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17111-6	11.5	255

## LIST OF PUBLICATIONS

- 1 Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. *Journal of Immunology*, **2009**, 183, 6330-7 5.3 50